Receptos Inc

Receptos — 2014 Joint ACTRIMS-ECTRIMS Meeting

17 slides from Receptos's conference presentation, Sep 15, 2014

  1. Slide 1: Phase 2 Results of the RADIANCE Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

    Exhibit 99.1 2014 Joint ACTRIMS-ECTRIMS Meeting Boston, Massachusetts Phase 2 Results of the RADIANCE Trial: A Randomized, Double-Blind, Placebo-Controlled Trial of Oral RPC1063 in Relapsing Multiple Sclerosis Amit Bar-Or, MD September 13, 2014 1 J Cohen , DL Arnold 2,3, G Comi 4, A Bar-Or 5, S Gujr

  2. Slide 2: Conflict of Interest Statements

    Conflict of Interest Statements Amit Bar-Or: financialsupportfrom BiogenIdec,DioGenix,Genentech, GlaxoSmithKline, Guthy-Jackson Charitable Foundation, Medimmune, Merck Serono, Novartis, Ono Pharmaceuticals, Receptos, Roche, Sanofi- Aventis, and Teva Neuroscience JCohen: financialsupportfrom EMDSeron

  3. Slide 3: Introduction

    Introduction Immunomodulation through the sphingosine 1-phosphate (S1P) receptor family is a validated therapeutic approach for the treatment of relapsing multiple sclerosis (RMS) RPC1063 is a novel, oral S1P1,5R modulator in clinical development for RMS by Receptos, Inc., which has only been previo

  4. Slide 4: RADIANCE Patient Population: Key Inclusion Criteria

    RADIANCE Patient Population: Key Inclusion Criteria MS, as diagnosed by the revised McDonald criteria (2010) Exhibiting a relapsing clinical course consistent with RMS and history of brain MRI lesions consistent with MS Ages 18-55 years, inclusive EDSS at Baseline between 0 and 5.0 points, inclusive

  5. Slide 5: RADIANCE Phase 2 Trial Design

    RADIANCE Phase 2 Trial Design 24-Week Placebo-Controlled Blinded Safety- 7-day 30-day Titration Treatment Period Extension Screening Period Period 1 mg RPC1063 1 mg RPC1063 Randomization 0.5 mg RPC1063 0.5 mg RPC1063 1 mg RPC1063 Placebo 0.5 mg RPC1063 Week -4 0 1 4 8 12 16 20 24 MRI Baseline Safety

  6. Slide 6: Patient Disposition

    Patient Disposition Randomized (N=258) Placebo (N=88) RPC1063 0.5 mg (N=87) RPC1063 1 mg (N=83) Discontinued 3 (3.4%) Discontinued 2 (2.3%) Discontinued 1 (1.2%) Adverse event 0 Adverse event 0 Adverse event 0 Lost to follow-up 1 (1.1%) Lost to follow-up 0 Lost to follow-up 0 Protocol violation 0 Pr

  7. Slide 7: Patient Demographics and RMS Disease History

    Patient Demographics and RMS Disease History Placebo RPC1063 0.5 mg RPC1063 1 mg Demographics (N=88) (N=87) (N=83) Female – n (%) 62 (70.5) 60 (69.0) 59 (71.1) Age (yrs) 39.0 (8.7) 38.1 (9.2) 38.4 (9.8) RMS Disease History, mean (SD) Years since MS diagnosis 4.6 (5.1) 2.8 (5.0) 3.6 (4.4) EDSS Score

  8. Slide 8: Primary Endpoint: Cumulative Number of Total GdE Lesions From Weeks 12 to 24

    Primary Endpoint: Cumulative Number of Total GdE Lesions From Weeks 12 to 24 14 12 11.1 10 8 86% decrease 86% decrease 6 p < 0.0001 p < 0.0001 4 2 1.5 1.5 0 Treatment Group Placebo (N=88) RPC1063 0.5 mg (N=87) RPC1063 1 mg (N=83) 13 September 2014 8 ACTRIMS-ECTRIMS 2014

  9. Slide 9: Secondary Endpoint (1): Mean Number of GdE Lesions at Week 24

    Secondary Endpoint (1): Mean Number of GdE Lesions at Week 24 3.5 3.2 3 2.5 2 91% decrease 94% decrease 1.5 p < 0.0001 p < 0.0001 1 0.5 0.3 0.2 0 Treatment Group Placebo (N=88) RPC1063 0.5 mg (N=87) RPC1063 1 mg (N=83) 13 September 2014 9 ACTRIMS-ECTRIMS 2014

  10. Slide 10: Secondary Endpoint (2): Cumulative Number of New or Enlarging T2 Lesions

    Secondary Endpoint (2): Cumulative Number of New or Enlarging T2 Lesions From Weeks 12 to 24 12 10 9.0 8 6 84% decrease 91% decrease p < 0.0001 p < 0.0001 4 2 1.4 0.8 0 Treatment Group Placebo (N=88) RPC1063 0.5 mg (N=87) RPC1063 1 mg (N=83) 13 September 2014 10 ACTRIMS-ECTRIMS 2014

  11. Slide 11: Secondary Endpoint (3): Annualized Relapse Rate

    Secondary Endpoint (3): Annualized Relapse Rate 0.6 0.5 0.5 31% decrease p = 0.271 53% decrease 0.4 p = 0.053 0.35 0.3 0.24 0.2 0.1 0 Treatment Group Placebo (N=88) RPC1063 0.5 mg (N=87) RPC1063 1 mg (N=83) 13 September 2014 11 ACTRIMS-ECTRIMS 2014

  12. Slide 12: Pharmacodynamic Effect of RPC1063

    Pharmacodynamic Effect of RPC1063: Mean ± SE Percent Change in Absolute Lymphocyte Counts 0 -20 -40 ~ 50% -60 ~ 60% 0 4 12 24 Study Week Program: E:\SASData\rpc1063\201a\csr\prog\g_lymph.sas 08JUN2014 13 September 2014 12 ACTRIMS-ECTRIMS 2014

  13. Slide 13: Safety: Treatment Emergent Adverse Events

    SAFETY: Treatment Emergent Adverse Events, n (%) (All 24-week Double blind phase) Placebo RPC1063 0.5 mg RPC1063 1 mg (N=88) (N=87) (N=83) Number of subjects experiencing 1 TEAE 52 (59.1) 56 (64.4) 47 (56.6) 1 moderate or severe TEAE 23 (26.1) 24 (27.6) 13 (15.7) 1 severe TEAE 1 (1.1) 2 (2.3) 1 (1.2

  14. Slide 14: Safety: Serious TEAEs

    SAFETY: Serious TEAEs Only 3 Serious TEAEs (reported as unrelated) during the study RPC1063 RPC1063 Placebo 0.5 mg 1 mg (N=88) (N=87) (N=83) Preferred Term n (%) n (%) n (%) Total number of Serious TEAEs 0 3 0 Numberof Subjects with 1 Serious TEAE 0 3 (3.4) 0 Opticneuritis* 0 1 (1.1) 0 Somatoform au

  15. Slide 15: Safety: Non-Serious TEAEs

    SAFETY: Non-Serious TEAEs No notable cardiac, pulmonary, ophthalmologic, infectious or malignancy TEAEs were observed 3 TEAEs of elevated liver enzymes ( 3x ULN) without clinical signs/symptoms were observed Placebo RPC1063 0.5 mg RPC1063 1 mg Parameter (N=87) (N=85) (N=83) Alanine Aminotransferase

  16. Slide 16: Cardiac Safety Profile of RPC1063

    Cardiac Safety Profile of RPC1063 Overall Incidence of Cardiac TEAEs SYSTEM ORGAN CLASS Placebo RPC1063 0.5 mg RPC1063 1 mg Preferred Term (N=88) (N=87) (N=83) CARDIAC DISORDERS 2 (2.3%) 2 (2.3%) 1 (1.2%) Angina Pectoris 0 0 1 (1.2%) First Degree AV Block 1 (1.1%) 0 0 Palpitations 1 (1.1%) 2 (2.3%)

  17. Slide 17: Conclusions

    Conclusions Both doses of RPC1063 demonstrated large, significant and consistent reductions of all MRI measures of MS disease activity The overall tolerability and safety profile of RPC1063, including cardiac and hepatic safety results, suggests a favorable risk-benefit profile in the treatment of R

Receptos — 2014 Joint ACTRIMS-ECTRIMS Meeting on 6ix